Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


14 Items
Title  Creator  Group name  Publishing year 
Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies Figarol et al. EquipeJC 2024-06-27
Odours of cancerous mouse congeners: detection and attractiveness Gouzerh et al. EquipeAM 2022-04-15
Mouse Modeling Dissecting Macrophage-Breast Cancer Communication Uncovered Roles of PYK2 in Macrophage Recruitment and Breast Tumorigenesis Müller et al. EquipeAM 2022-03
Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma Chiavarina et al. EquipeJC 2022-03
Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia Xiong et al. EquipeAP 2021
MAGI1 inhibits the AMOTL2/p38 stress pathway and prevents luminal breast tumorigenesis Kantar et al. EquipeAM 12/2021
Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance Mancini et al. EquipeAM 2021-07-09
Dissociated response related to corticosteroids in lung cancer treated by immunotherapy: A case report Thomas et al. EquipeAM 05/2021
The evolution of resistance and tolerance as cancer defences Thomas et al. EquipeAM 2020-03
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma Bousquet Mur et al. EquipeAM 2020-02-03
Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma Nokin et al. EquipeAM 2020-08-06
An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors Mancini et al. EquipeAM 02 2018
Troponin-I enhances and is required for oncogenic overgrowth Casas-Tintó et al. EquipeAM Aug 16, 2016
Therapeutic effect of ?-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK Maraver et al. EquipeAM Aug 14, 2012
14 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés